JP2023527365A5 - - Google Patents
Info
- Publication number
- JP2023527365A5 JP2023527365A5 JP2022572586A JP2022572586A JP2023527365A5 JP 2023527365 A5 JP2023527365 A5 JP 2023527365A5 JP 2022572586 A JP2022572586 A JP 2022572586A JP 2022572586 A JP2022572586 A JP 2022572586A JP 2023527365 A5 JP2023527365 A5 JP 2023527365A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- drug
- enpp1
- enpp3
- stent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063030870P | 2020-05-27 | 2020-05-27 | |
| US63/030,870 | 2020-05-27 | ||
| PCT/US2021/034576 WO2021243054A1 (en) | 2020-05-27 | 2021-05-27 | Compositions and methods for inhibiting vascular smooth muscle cell proliferation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527365A JP2023527365A (ja) | 2023-06-28 |
| JP2023527365A5 true JP2023527365A5 (https=) | 2024-06-04 |
Family
ID=78722799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572586A Pending JP2023527365A (ja) | 2020-05-27 | 2021-05-27 | 血管平滑筋細胞増殖を阻害するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230330307A1 (https=) |
| EP (1) | EP4157328A4 (https=) |
| JP (1) | JP2023527365A (https=) |
| KR (1) | KR20230047334A (https=) |
| CN (1) | CN116367851A (https=) |
| AU (1) | AU2021281267A1 (https=) |
| CA (1) | CA3180119A1 (https=) |
| CO (1) | CO2022018016A2 (https=) |
| IL (1) | IL298482A (https=) |
| MX (1) | MX2022014733A (https=) |
| TW (1) | TW202214293A (https=) |
| WO (1) | WO2021243054A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023196820A2 (en) * | 2022-04-04 | 2023-10-12 | Inozyme Pharma, Inc. | Treatment of enpp1 deficiency and abcc6 deficiency |
| CN115433776B (zh) * | 2022-09-30 | 2023-12-22 | 中国医学科学院阜外医院 | Ccn3在调控血管平滑肌细胞钙化中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005086831A2 (en) * | 2004-03-10 | 2005-09-22 | Orbus Medical Technologies, Inc. | Endothelial ligand binding coated medical device |
| US11039942B2 (en) * | 2006-06-13 | 2021-06-22 | Sino Medical Sciences Technology Inc. | Drug eluting stent and method of use of the same for enabling restoration of functional endothelial cell layers |
| EP3471747A1 (en) * | 2016-06-16 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Methods of treating myointimal proliferation |
| US12134790B2 (en) * | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| AU2019267545A1 (en) * | 2018-05-08 | 2020-11-26 | Yale University | Compositions and methods for reducing progression of nephrolithiasis |
| CN120383683A (zh) * | 2018-08-31 | 2025-07-29 | 耶鲁大学 | Enpp1多肽及其使用方法 |
-
2021
- 2021-05-27 KR KR1020227045745A patent/KR20230047334A/ko active Pending
- 2021-05-27 WO PCT/US2021/034576 patent/WO2021243054A1/en not_active Ceased
- 2021-05-27 TW TW110119287A patent/TW202214293A/zh unknown
- 2021-05-27 JP JP2022572586A patent/JP2023527365A/ja active Pending
- 2021-05-27 CA CA3180119A patent/CA3180119A1/en active Pending
- 2021-05-27 IL IL298482A patent/IL298482A/en unknown
- 2021-05-27 MX MX2022014733A patent/MX2022014733A/es unknown
- 2021-05-27 EP EP21812363.6A patent/EP4157328A4/en active Pending
- 2021-05-27 AU AU2021281267A patent/AU2021281267A1/en active Pending
- 2021-05-27 CN CN202180043445.6A patent/CN116367851A/zh active Pending
-
2022
- 2022-11-23 US US18/058,712 patent/US20230330307A1/en active Pending
- 2022-12-13 CO CONC2022/0018016A patent/CO2022018016A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Taddei et al. | Inhibitory effect of full-length human endostatin on in vitro angiogenesis | |
| Lawrence et al. | Rapamycin suppresses experimental aortic aneurysm growth | |
| Kong et al. | Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells | |
| US6218372B1 (en) | Methods for treating restenosis with p21 | |
| JP2020508068A5 (https=) | ||
| RU2311910C2 (ru) | Ингибирование stat-1 | |
| JP2023527365A5 (https=) | ||
| JP2002523036A (ja) | イムノフュージンとしての新脈管形成インヒビターの発現および輸送 | |
| JP2001503755A (ja) | Ｎｏまたはプロスタサイクリン産生を刺激する薬剤の治療的使用およびデリバリー装置 | |
| KR20040081418A (ko) | 약물의 국소투여를 통한 재협착의 예방 및 치료 | |
| JP2001520238A (ja) | 低毒性のヒトインターフェロン−αアナログ | |
| CA2259228A1 (en) | Adenoviral mediated gene transfer in adipocytes and related implants | |
| JP2002510655A (ja) | 免疫抑制剤としての間葉幹細胞によるｔ細胞応答を阻害する方法とその利用 | |
| JPH09509324A (ja) | 増殖阻止ホメオボックス遺伝子 | |
| JPH0692318B2 (ja) | 不要細胞の分解あるいは阻止物質からなる治療剤 | |
| JP2023527364A5 (https=) | ||
| Miyake et al. | Inhibition of anastomotic intimal hyperplasia using a chimeric decoy strategy against NFκB and E2F in a rabbit model | |
| Fishbein et al. | Site specific gene delivery in the cardiovascular system | |
| Bergese et al. | Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Roles for TNF and IL4 | |
| CN105079780B (zh) | 一种特异结合trb3的多肽在治疗腹主动脉瘤中的应用 | |
| Fishbein et al. | Endovascular gene delivery from a stent platform: gene-eluting stents | |
| Chung et al. | Blockade of TGF-β by catheter-based local intravascular gene delivery does not alter the in-stent neointimal response, but enhances inflammation in pig coronary arteries | |
| JP2023532732A5 (https=) | ||
| AU765167B2 (en) | Targeting of molecules to large vessel endothelium using EPCR | |
| Lien et al. | Gene therapy for renal disorders: what are the benefits for the elderly? |